Examples: in the context of prodromal Alzheimer’s disease, engineered synbiotics plus CB2-biased agonists were assessed using both tau-PET slope and re-establishment of rhythmicity in both bile acid and endocannabinoid profiles; in the context of MS relapse prevention, synchronization of microbial–cytokine oscillations; and in the context of depression, reduction in endocannabinoid recovery time post-stress [241]. The gene discussed is MAPT; the disease is depressive symptom measurement.